| 26.575 -1.575 (-5.6%) | 04-21 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 32.08 |
1-year : | 34.8 |
| Resists | First : | 27.47 |
Second : | 29.79 |
| Pivot price | 27.37  |
|||
| Supports | First : | 23.7 |
Second : | 19.72 |
| MAs | MA(5) : | 28.3 |
MA(20) : | 27.04 |
| MA(100) : | 24.92 |
MA(250) : | 18.87 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 65.1 |
D(3) : | 76.4 |
| RSI | RSI(14): 47.4 |
|||
| 52-week | High : | 29.79 | Low : | 5.48 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PRPO ] has closed above bottom band by 36.1%. Bollinger Bands are 15.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.18 - 28.38 | 28.38 - 28.53 |
| Low: | 25.66 - 25.91 | 25.91 - 26.11 |
| Close: | 26.22 - 26.57 | 26.57 - 26.83 |
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; ICE-COLD PCR, a proprietary and patented specimen technology that increases the sensitivity of molecular based tests; and COVID-19 antibody tests. It sells ICE-COLD-PCR technology kits to bio-pharma customers. Precipio, Inc. has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. The company is based in New Haven, Connecticut.
Fri, 17 Apr 2026
Board member for Precipio (NASDAQ: PRPO) receives 93-share grant - Stock Titan
Fri, 17 Apr 2026
Stock grant lifts Precipio (PRPO) director Cossman to 16,133 shares - Stock Titan
Fri, 17 Apr 2026
Precipio (PRPO) director paid in stock grant for Q1 board service - Stock Titan
Fri, 10 Apr 2026
Precipio COO Sabet Ahmed Zaki buys $530 in PRPO stock - Investing.com
Fri, 03 Apr 2026
How Precipio Inc. (PRPO) Affects Rotational Strategy Timing - Stock Traders Daily
Thu, 02 Apr 2026
Earnings call transcript: Precipio Inc. hits financial inflection in Q4 2025 - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 11.8 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 4 (K) |
| EPS | -0.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.18 |
| Profit Margin | -1.6 % |
| Operating Margin | 8 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -2.8 % |
| Qtrly Rev. Growth | 22.8 % |
| Gross Profit (p.s.) | 6.01 |
| Sales Per Share | 13.51 |
| EBITDA (p.s.) | 0.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -115.55 |
| PEG Ratio | 0 |
| Price to Book value | 3.24 |
| Price to Sales | 1.96 |
| Price to Cash Flow | 69.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|